Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: The role of empagliflozin-induced metabolic changes for cardiac function in patients with type 2 diabetes. A randomized cross-over magnetic resonance imaging study with insulin as comparator

Fig. 1

Study outline. Participants were included, to undergo a washout period, a run-in period of empagliflozin, and then another washout period before being randomized to either empagliflozin or insulin treatment first. After the initial treatment period, participants underwent a third washout periode before receiving the remaining drug (empagliflozin or insulin depending on the randomized order of study drugs)

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840